PMC2963141_01
Endometrial curetting prior to therapy, irregular cribriform glands, and mild atypia: well-differentiated endometrioid carcinoma (H&E 100x).
OGI2010-431950.001.jpg
PMC2963141_01_OGI2010-431950.001.jpg
fig1
An outpatient endometrial pipelle biopsy was performed which revealed a moderately differentiated adenocarcinoma (Figure 1) with minimal myometrial invasion (Clinical FIGO stage I).
T-shaped Femilis LNG-IUS with 28 mm long crossarm and 3 cm long and 2.4 mm wide drug delivery compartment.
OGI2010-431950.002.jpg
PMC2963141_01_OGI2010-431950.002.jpg
fig2
An LNG-IUS (Femilis, Contrel Research, Ghent, Belgium) releasing 20 mug of LNG/d was inserted (Figure 2), and advice was given to request a repeat biopsy within the next 3 to 6 months.
Sonographic view of uterus with LNG-IUS in situ. The endometrial thickness is 3.42 mm.
OGI2010-431950.003.jpg
PMC2963141_01_OGI2010-431950.003.jpg
fig3
The endometrium showed normal thickness, and there was no evidence of any endometrial abnormality or myometrial invasion (Figures 3 and 4).
3D-sonographic view of normal uterus (transverse section) with LNG-IUS in center.
OGI2010-431950.004.jpg
PMC2963141_01_OGI2010-431950.004.jpg
fig4
The endometrium showed normal thickness, and there was no evidence of any endometrial abnormality or myometrial invasion (Figures 3 and 4).
Endometrial curetting posttherapy, small regular glands with tubal metaplasia, surrounded by decidualised stroma (H&E 100x).
OGI2010-431950.005.jpg
PMC2963141_01_OGI2010-431950.005.jpg
fig5
Histological examination of the specimen revealed a secretory endometrium without signs of hyperplasia or atypia (Figure 5).